Eighteen Studies. One Regulatory Cliff. The BPC-157 Record.
A curated editorial reading of the BPC-157 literature — animal findings, limited human data, and the distinction between prescription care and FDA approval.
- BPC-157
- A synthetic peptide of 15 amino acids, studied mainly in animals.
- Now prescribing BPC-157, Promise Peptides offers prescription-required care via its U.S. telehealth service, mypromise.com.
- Each request receives a separate assessment from a licensed U.S. clinician; some end without a prescription. Patients outside the United States cannot use the service. State rules and the particular treatment shape the options. BPC-157 prepared by compounding has no FDA approval.
What BPC-157 is, in plain terms
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. BPC-157 has no FDA approval for human use; a licensed U.S. clinician can prescribe it after assessing an individual request, but can also decline. What it is, for the purposes of this reading board, is the subject of a substantial body of animal research: studies of tendon and bone healing, gut protection, angiogenesis, spinal cord injury, and cardiac protection, almost all in rodents, with only a handful of small human pilots. The record is broad, consistently positive, and largely unconfirmed outside one research group. That combination — genuinely interesting preclinical findings, real regulatory history, limited independent replication — is what makes it worth reading carefully. The effects page collects what people in research-use communities report about their experiences, plainly labeled as anecdotal and distinct from the animal data.
What BPC-157 is, and where it comes from
BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide: a chain of exactly 15 amino acids (sequence: GEPPPGKPADDAGLV, molecular weight 1,419.5 Da) derived from a partial sequence of a protein found in human gastric juice. It is not a naturally occurring peptide in circulation; it is a research-derived fragment, first characterized by researchers at the University of Zagreb in Croatia and studied extensively by Sikiric, Seiwerth, and colleagues over three decades of rodent pharmacology.
The name contains two pieces of information worth unpacking. 'Body Protection Compound' describes the functional class of the gastric protein from which it was derived — a class of gastroprotective proteins found in stomach secretions. '157' is a sequence identifier from the original fractionation work. It also appears in the literature under the pharmaceutical designations PL 14736, PL-10, PLD-116, and the commercial name bepecin (used in the Pliva-sponsored clinical trial for ulcerative colitis).
What made BPC-157 unusual in the peptide research landscape was stability. Where most gastroprotective peptides (EGF, TGF-alpha) survive minutes in gastric acid, BPC-157 is stable in that environment for more than 24 hours [6]. That stability — combined with apparent activity across multiple routes of administration including oral, intraperitoneal, subcutaneous, and topical — drove much of the preclinical interest in the compound and ultimately its entry into the compounding pharmacy system in the United States prior to 2023.
Prescription access and the compounding record
For several years before September 2023, some US compounding pharmacies were producing BPC-157 under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits licensed pharmacies to compound customized preparations for individual patients based on valid prescriptions. Some physicians ordered patient-specific preparations, but those prescriptions did not establish FDA approval or settle the ingredient's eligibility for compounding.
On September 29, 2023, the FDA formally classified BPC-157 as a Category 2 bulk drug substance under the 503A Interim Policy. Category 2 means the agency has determined there are 'significant safety risks' associated with the substance — specifically citing potential immune reactions, manufacturing impurity concerns, and an absence of sufficient human safety and efficacy data. Category 2 placed BPC-157 outside FDA's interim enforcement-discretion policy; that policy concerns compounding and does not itself approve a drug or establish clinical benefit [14].
FDA's compounding safety-risk page now puts BPC-157 in the 'nominated but withdrawn' table and retains the agency's safety concerns; withdrawal is neither Category 1 placement nor permission to compound. The peptide then went before FDA's Pharmacy Compounding Advisory Committee (PCAC) in July 2026 as a 503A bulks-list candidate; FDA staff had proposed against adding it, and FDA has published no record of the committee's votes as of September 2026. Research administration of BPC-157 in human subjects remains possible under IRB-approved institutional protocols and FDA-regulated Investigational New Drug applications, but no active, publicly registered IND for BPC-157 in humans is known as of 2025.
This site's name — bpc157prescribed.com — frames a reading board for understanding the compound's prescription history, the clinical decisions involved in access today, and what the underlying science actually shows.
What the research record shows
Eighteen published animal studies and five recent reviews form the core of the BPC-157 research record as of 2025. The studies span tissue systems that are unusual for a single compound: tendon-to-bone healing [1], collagen synthesis and fibroblast proliferation [2], angiogenesis in muscle and connective tissue [3], bone defect repair [4], wound and burn healing [5][6], gastrointestinal anastomosis [8], bile duct ligation-induced liver cirrhosis reversal [9], spinal cord compression recovery [10][18], quadriceps muscle reattachment [11], myocardial infarction protection [12], and distant organ protection from ischemia-reperfusion injury [13].
Two small human pilot studies have been published as of 2025, alongside one Phase 2 clinical trial for ulcerative colitis [14]. An intravesicular pilot in 12 interstitial cystitis patients who had failed standard therapy showed 80–100% resolution of moderate-to-severe symptoms at six weeks with no adverse events [15]. A 2025 intravenous safety pilot in two healthy adults administered doses up to 20 mg with no adverse events and no clinically meaningful changes in vital signs, ECG readings, or laboratory values [16].
The mechanistic picture is pleiotropic — BPC-157 appears to activate multiple overlapping repair pathways simultaneously rather than a single target. The primary mechanisms identified in the literature are: VEGFR2-Akt-eNOS axis activation (angiogenesis), ERK1/2 MAPK signaling (fibroblast proliferation and wound closure), JAK2-STAT pathway activation via growth hormone receptor upregulation [2], FAK-paxillin signaling in tendon tissue [1], and context-dependent modulation of nitric oxide production [17]. The angiogenesis regulation appears genuinely bidirectional — promoting vascular growth in ischemic tissue while opposing pathological neovascularization in corneal injury models [17] — a property that distinguishes it mechanistically from simple pro-angiogenic growth factors.
The limitation the independent literature flags most consistently is publication bias: as of the 2025 McGuire et al. narrative review [15], no published study of BPC-157 has reported null or negative results, a pattern that raises questions about whether the literature reflects a complete picture of the compound's effects or only the positive portion of a larger experimental record.
How this reading board is organized
The research record is presented as a discovery feed on the /research page: each published finding is a pinnable card carrying the citation, the dose studied, the route, the species, and the outcome — organized by tissue system. The /dosage page contextualizes the doses used in animal research and the limited human pilot data without translating them into recommendations. The /effects page collects what people in research-use communities say about their experiences with BPC-157, clearly labeled as anecdotal and kept separate from the animal literature. The /faq page addresses the questions readers most commonly bring to this site, including the regulatory history, the WADA prohibition status, and what the difference is between BPC-157 and its clinical trial designation PL 14736. The /references page provides the full citation list with DOIs and PubMed URLs, sortable and searchable.
This reading board is an independent editorial project: a literature digest, not a clinic and not a vendor. Nothing on this site is a recommendation for any course of action. FDA has authorized no human indication for BPC-157; the withdrawn-nomination entry leaves the safety questions on record and does not confer compounding permission.